A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2006
10/26/2006	WO2005112911A3 Compositions and methods for treating myelin deficiency disorders
10/26/2006	WO2005112633A3 Compounds and compositions for delivering active agents
10/26/2006	WO2005102301A3 Hydroxymethylbutyrate compositions and uses thereof
10/26/2006	WO2005100363A8 (poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents
10/26/2006	WO2005099758A3 Injectable bioartificial tissue matrix
10/26/2006	WO2005091891A3 Compositions and methods for preventing and treating skin and hair conditions
10/26/2006	WO2005082338A3 Prodrugs for the intravenous administration of proton pump inhibitors
10/26/2006	WO2005072408A3 Treating a viral disorder
10/26/2006	WO2005070008A8 Polymer no donor predrug nanofiber coating for medical devices and therapy
10/26/2006	WO2005067460A3 Epha2 vaccines
10/26/2006	WO2005060542A3 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
10/26/2006	WO2005041891A3 Neutrophil activation by immune response modifier compounds
10/26/2006	WO2003006628A3 Nad synthetase inhibitors and uses thereof
10/26/2006	US20060241311 Noval polymorphs of atovaquone and process of
10/26/2006	US20060241305 Amorphous form of losartan potassium
10/26/2006	US20060241303 Piperidine derivatives and process for their production
10/26/2006	US20060241296 Vanilloid receptor ligands and their use in treatments
10/26/2006	US20060241191 Crystalline levosalbutamol sulphate and polymorphic forms thereof
10/26/2006	US20060241190 Keratolytic composition with anti-allergic anti-inflammatory properties
10/26/2006	US20060241189 Sertraline hydrochloride polymorphs
10/26/2006	US20060241188 Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors
10/26/2006	US20060241187 2,2-bis(4-(4-amino-3-hydroxyphenoxy)phenyl)adamantane; arrest and differentiation in human colon cancer cells; less toxic; reacting an aromatic diol with at least one 5-halo-2-nitrophenol in the presence of at least one inorganic base in an organic solvent;
10/26/2006	US20060241186 Alkylating agent combinations in the treatment of cancer
10/26/2006	US20060241185 Antibiotics targeting MreB
10/26/2006	US20060241184 Medicament for treatment of nocturia
10/26/2006	US20060241183 Compositions and methods of using D-DOPA to treat Parkinson's disease
10/26/2006	US20060241182 Antibiotic, functional cosmetic and functional food containing levulinic acid and their derivatives
10/26/2006	US20060241181 Alpha-ketoglutarates of active ingredients and compositions containing same
10/26/2006	US20060241180 Selective androgen receptor modulators and methods of use thereof
10/26/2006	US20060241179 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
10/26/2006	US20060241178 Compositions and methods for treating lung cancer
10/26/2006	US20060241177 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
10/26/2006	US20060241176 Dihydrobenzofuran derivatives and uses thereof
10/26/2006	US20060241175 solubilizing a nonsteroidal antiinflammatory drug (NSAID) such as diclofenac by combining with at least two of camphor, menthol and thymol
10/26/2006	US20060241174 Vitamin E tocotrienols inhibition of intracellularly obligate pathogen Chlamydia and methods of use
10/26/2006	US20060241173 Compound
10/26/2006	US20060241172 Benzodioxane and benzodioxolane derivatives and uses thereof
10/26/2006	US20060241171 Novel physiologically active substances
10/26/2006	US20060241170 Methods and formulations of taxanes
10/26/2006	US20060241169 Crystalline forms of [R-(R.R)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
10/26/2006	US20060241168 administering a protein kinase B activating agent comprising (R)-5,6-dimethoxy-2-[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-benzofuran-5-yl]isoindoline; treating depression, posttraumatic stress disorder, Parkinson's disease, Alzheimer's diseases
10/26/2006	US20060241167 Crystalline polymorph Form G, formed by filtering Fluvastatin sodium off from an aqueous suspension.
10/26/2006	US20060241166 Sapphyrins and uses thereof
10/26/2006	US20060241165 Method and kit for regulation of microvascular tone
10/26/2006	US20060241164 Pharmacological treatment for sleep apnea
10/26/2006	US20060241163 Optically active (S)-hydantoin derivative
10/26/2006	US20060241162 Optically active (R)-hydantoin derivative
10/26/2006	US20060241161 Process for preparing losartan potassium with improved flowability
10/26/2006	US20060241160 Zolmitriptan crystal forms
10/26/2006	US20060241159 Zolmitriptan crystal forms
10/26/2006	US20060241158 Zolmitriptan crystal forms
10/26/2006	US20060241157 Heterocyclic ppar modulators
10/26/2006	US20060241156 Preparation of epothilone derivatives
10/26/2006	US20060241155 TNF-alpha production inhibitors
10/26/2006	US20060241154 Benzotropolone derivatives and modulation of inflammatory response
10/26/2006	US20060241153 N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility
10/26/2006	US20060241152 Imidazoline derivatives having CB1-antagonistic activity
10/26/2006	US20060241151 Pyrid-2-one derivatives and methods of use
10/26/2006	US20060241150 P38 kinase inhibitor compositions and methods of using the same
10/26/2006	US20060241149 Chemical compounds
10/26/2006	US20060241148 Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
10/26/2006	US20060241147 Pyridine derivatives useful for inhibiting sodium/calcium exchange system
10/26/2006	US20060241146 2-cyano-1-[t-4-(4-acetyl-1-piperazinyl)-1-methyl-r-1-cyclohexylamino]acetylpyrrolidine; dipeptidylpeptidase IV (DPPIV) inhibitor; antidiabetic, insulin resistance, hyperglycemia, obesity; antiproliferative agent for T-cell, HIV, AIDS; arthritis, osteoporosis
10/26/2006	US20060241145 Piperidine derivative crystal, process for producing the same, and use
10/26/2006	US20060241144 Method for treating apathy syndrome
10/26/2006	US20060241143 Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety
10/26/2006	US20060241142 Naphthamide derivatives and their use
10/26/2006	US20060241141 Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin
10/26/2006	US20060241140 Imidazolamino compounds
10/26/2006	US20060241139 Treatment of DNA damage related disorders
10/26/2006	US20060241138 Heterocyclic amide derivatives for the treatment of diabetes and other diseases
10/26/2006	US20060241137 Triazole compounds and the therapeutic use thereof
10/26/2006	US20060241136 Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist
10/26/2006	US20060241135 5-[3-(1-methylethoxy)phenyl]-2,4-di-methyl-2-azabicyclo[3.3.1]nonan-7-one; analgesic; drug resistance; side effect reduction; headache, muscle strains and sprains, arthritis, trauma, surgery, and back injuries, cancer pain, osteoarthritis, rheumatoid arthritis, or neuropathic pain
10/26/2006	US20060241134 Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
10/26/2006	US20060241133 Electrically variable pneumatic structural element
10/26/2006	US20060241132 Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient
10/26/2006	US20060241131 Pyrrolo[2,3-d]pyrimidine compounds
10/26/2006	US20060241130 Anti-inflammatory compositions and uses thereof
10/26/2006	US20060241129 Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
10/26/2006	US20060241127 N-[2-Amino-6-(4-pyridinyl)-4-pyrimidinyl]-N-[2-fluoro-4-(1H-pyrrolo[2,3-b]-pyridin-4-yloxy)phenyl]amine, used for the treatment and/or prophylaxis of cardiovascular diseases and erectile dysfunction
10/26/2006	US20060241126 Phospholipase inhibitors perticularly phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2; N-(1-Methylpiperidin-4-yl)-(2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H-pyrido[2,3-d]pyrimidin-1-yl)-N-(4-(4-trifluoromethylphenyl)phenyl)methylacetamide; amidation
10/26/2006	US20060241125 Compounds useful in therapy
10/26/2006	US20060241124 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety
10/26/2006	US20060241123 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
10/26/2006	US20060241122 Combination therapy for the treatment of neoplasms
10/26/2006	US20060241121 Substituted piperazines as CB1 antagonists
10/26/2006	US20060241120 Cannabinoid Receptor Ligands and Uses Thereof
10/26/2006	US20060241119 Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
10/26/2006	US20060241118 Hydroxamate sulfonamides as cd23 shedding inhibitors
10/26/2006	US20060241117 Therapeutic agents useful for treating pain
10/26/2006	US20060241116 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates
10/26/2006	US20060241115 2,3-Dihydro-4H-1,4-benzoxazine derivatives containing an optionally fused pyridine or pyrimidine ring; 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-phenyl-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide; kinase inhibitors; inflammation, angiogenesis and cancer
10/26/2006	US20060241114 Derivatives of azasugars as anticancer agents
10/26/2006	US20060241113 Polyarylcarboxamides useful as lipid lowering agents
10/26/2006	US20060241112 Kinase inhibitors
10/26/2006	US20060241111 inhibitors of coagulation factor Xa such as 1-(5-chlorothien-2-ylcarbonyl)-4-[4-(3-oxomorpholin-4-yl)phenyl]-2-propylsemicarbazide, used for preventing thrombosis, infarction, arteriosclerosis, inflammation, bleeding, angina pectoris, restenosis, intermittent claudication and treatment of tumors
10/26/2006	US20060241110 2-(Imidazol-1-ylalkyl)-3H-quinazolin-4-one derivatives; mitotic kinesin KSP inhibitors; anticarcinogenic, antiinflammatory, and antiproliferative agents
10/26/2006	US20060241109 PGD2 receptor antagonists for the treatment of inflammatory diseases
10/26/2006	US20060241108 Substituted phenoxazines and acridones as inhibitors of AKT

1 ... 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 4044 4045 4046 4047 4048 4049 4050 4051 4052 4053 ... 7860